NasdaqGS - Nasdaq Real Time Price USD
Atara Biotherapeutics, Inc. (ATRA)
6.67
-0.17
(-2.49%)
As of 1:07:53 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 2 |
| Avg. Estimate | -0.32 | -0.32 | 2.27 | -0.19 |
| Low Estimate | -0.32 | -0.32 | 2.27 | -0.35 |
| High Estimate | -0.32 | -0.32 | 2.27 | -0.04 |
| Year Ago EPS | -3.1 | -2.93 | -11.41 | 2.27 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 3 |
| Avg. Estimate | -- | -- | 98.15M | 31.67M |
| Low Estimate | -- | -- | 98.15M | 3M |
| High Estimate | -- | -- | 98.15M | 60M |
| Year Ago Sales | 28.64M | 40.19M | 128.94M | 98.15M |
| Sales Growth (year/est) | -100.00% | -100.00% | -23.88% | -67.74% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -2.24 | -3.5 | -3.49 | -1.92 |
| EPS Actual | -3.1 | -2.93 | -1.19 | 3.5 |
| Difference | -0.86 | 0.57 | 2.3 | 5.43 |
| Surprise % | -38.52% | 16.24% | 65.88% | 281.82% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.32 | -0.32 | 2.27 | -0.19 |
| 7 Days Ago | -1.32 | -1.29 | -5.8 | -1.38 |
| 30 Days Ago | -1.32 | -1.29 | -5.8 | -1.38 |
| 60 Days Ago | -1.53 | -1.15 | -5.84 | -0.87 |
| 90 Days Ago | -3.43 | 1.15 | -7.83 | -4.85 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 2 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ATRA | 89.68% | 89.08% | 119.89% | -108.59% |
| S&P 500 | 13.32% | 2.67% | 7.78% | 13.75% |
Upgrades & Downgrades
| Maintains | Canaccord Genuity: Buy to Buy | 3/11/2025 |
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 1/22/2025 |
| Maintains | Canaccord Genuity: Buy to Buy | 1/17/2025 |
| Initiated | Rodman & Renshaw: Buy | 12/20/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 11/13/2024 |
| Reiterates | HC Wainwright & Co.: Neutral | 8/21/2024 |
Related Tickers
MIST Milestone Pharmaceuticals Inc.
1.3005
+6.60%
ABEO Abeona Therapeutics Inc.
6.15
+0.82%
KPTI Karyopharm Therapeutics Inc.
5.0000
-6.02%
RGNX REGENXBIO Inc.
9.28
+4.33%
ALLO Allogene Therapeutics, Inc.
1.1150
+0.45%
CHRS Coherus BioSciences, Inc.
0.8000
+5.13%
MGNX MacroGenics, Inc.
1.5800
0.00%
VSTM Verastem, Inc.
7.61
+0.26%
ITOS iTeos Therapeutics, Inc.
8.52
+9.09%
CAPR Capricor Therapeutics, Inc.
10.11
+7.09%